- €6.19bn
- €17.49bn
- €7.52bn
Brief: Grifols Gets FDA Approval For New Fibrinogen Concentrate, Fesiltytm
Brief: Grifols Gets EMA Approval For Manufacture And Selling Of Egyptian Plasma
Brief: Grifols Achieves Self-Sufficiency In Plasma-Derived Medicines In Egypt
Brief: Grifols Gets FDA Approval For Thrombate III In Pediatric Patients In U.S.
Brief: Grifols Gets Regulatory Approval For Fibrinogen Concentrate In Germany
Spanish stocks - Factors to watch on Nov 13
Brief: Grifols Secures 95% Of Investor Support To Improve Documentation Terms Of Its 1.3 Bln Euros Secured Notes
FX headwinds, pipeline delays weigh on Grifols' shares
Spanish stocks - Factors to watch on Nov 5
Brief: Grifols Q3 Net Profit 127 Mln Euros
Brief: Grifols Q3 Adjusted EBITDA EUR 482 Million
Brief: Grifols Expands Diagnostic Production Capacity In US With New Plant In San Diego
Spanish stocks - Factors to watch on Oct 10
Brief: Grifols' Biotest Launches Immunodeficiencies Medicine Yimmugo In U.S.
Spanish court summons Gotham City founder in Grifols share price probe (updated)
Spanish court summons Gotham City founder in Grifols share price probe
Brief: Spain's High Court Summons Gotham City, GIP Managers For Market-Related Offence Regarding Grifols
Brief: Grifols Creates Strategy Committee To Advise Board
Spanish stocks - Factors to watch on Aug 7